Biotech Investment Analyst - Drug Asset & Company Assessment
Why This Role Stands Out
Leverage your expertise in biotech and pharma asset assessment within a cutting-edge AI company, contributing to the future of drug evaluation with significant hourly compensation. This remote role is ideal for experienced investment analysts who thrive on dissecting complex data and shaping innovative evaluation frameworks. Apply now to be part of a groundbreaking pilot program with excellent potential for ongoing engagement.
Quick Overview
Job Description
This role is for one of our clients
Compensation: $120 - $200 per hour
We are partnering with a biotech and pharma research team on expert human-evaluation work — creating and critiquing rubrics that analyze commercial drugs and drug-development programs. We're seeking a biotech investment analyst (specialist-fund background) for a paid pilot, with the potential to continue as the work scales.
Responsibilities
- Create and critique rubrics that analyze commercial drugs and drug-development programs
- Provide overall company and asset assessment — mechanism, clinical data, competitive position, and value drivers
- Judge the quality of an investment-style thesis and flag weak, overconfident, or missing assumptions
- Apply your assessment across the pilot's set of companies (~5–10)
Requirements
- US-based biotech / healthcare investment analyst with a specialist-fund background
- Familiarity with biotech/pharma development programs
- Able to assess a drug asset and the company behind it end-to-end
- 5+ years evaluating biotech/pharma companies or assets
Engagement Details
- Duration: Approximately 10–20 hours over a 1–2 week pilot
- Remote — US-based
Why Participate
- Help improve expert AI evaluation of drugs and drug-development programs
- Recurring engagement for strong contributors
We consider all qualified applicants without regard to legally protected characteristics and provide reasonable accommodations upon request.